PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002 - JUNS News | RalliesPharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002
J
JUNS• License deal terms for Ala-002
- PharmAla Biotech executes definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to Ala-002.
- The deal is valued at up to $100 million, including a $3.33 million upfront payment and milestones plus royalties.
- The upfront payment of $3.33 million consists of $1.50 million cash and $1.83 million in Jupiter stock.
- Development and regulatory milestones total up to $23.33 million, including $20 million for FDA approval.
- Commercialization milestones total up to $73.33 million based on U.S. net sales targets.
- PharmAla Biotech will receive a 3% royalty on U.S. net sales after the third milestone.
- PharmAla Biotech will manufacture GMP-grade Ala-002 for Jupiter under a separate supply agreement.
SRV
•
